榮昌生物-B(9995.HK)上市 首日收漲33.97% 市值近334億港元
格隆匯11月9日丨創新生物藥公司榮昌生物-B(9995.HK)今日在香港交易所掛牌上市,早盤高開16.31%,收盤報69.8港元/股,漲幅33.97%,市值近334億港元。該股IPO價格為52.1港元,公開發售獲53.43倍認購。據悉,公司致力於開發和商業化同類首創和同類最佳的生物藥,用於治療自身免疫(系統性紅斑狼瘡SLE)、腫瘤科和眼科疾病。公司核心產品泰它西普不僅在系統性紅斑狼瘡的治療上實現了重要突破,還有潛力用於其它多種擁有巨大未滿足臨牀需求的自身免疫適應症,目標市場銷售收益年複合增長率29.3%,預期將於2020年第四季度獲得有條件的上市許可並實現銷售。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.